Is Vertex Pharmaceuticals Incorporated overvalued?

Vertex Pharmaceuticals Incorporated (VRTX) looks overvalued — trading about 25% above its fair value.

Overvalued

Price

$491.34

Fair value

$370.11

Current P/E

32.1

Normal P/E

24.2

Market cap

$124.70B

Dividend yield

0.0%

Return on equity

21.2%

Sector

Healthcare

Fair value compares VRTX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 28 Jun 2026.

Related stocks